Novel combo shows promise in small cell neuroendocrine mCRPC
Combination therapy with the novel agent BXCL701 and pembrolizumab showed strong clinical activity in in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer.
Real-world study investigates first-line avelumab maintenance for metastatic urothelial carcinoma
Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.
Sabizabulin active in metastatic castration-resistant prostate cancer
The utilization of sabizabulin in patients yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099) presented at the 2022 AUA Annual Meeting.
Dr. Bakouny details ongoing research in translocation renal cell carcinoma
Ziad Bakouny, MD, MSc, highlights efforts to gain an understanding of the biology and genomic drivers of the rare and aggressive form of kidney cancer.
2 Clarke Drive Cranbury, NJ 08512